Summit Therapeutics (SMMT) Capital Expenditures (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Capital Expenditures data on file, last reported at $217000.0 in Q2 2026.

• Quarterly Capital Expenditures fell 90.37% year-over-year to $217000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.8 million (down 128.34% YoY) and the FY2025 annual result came in at $657000.0, up 372.66% from the prior year.
• Capital Expenditures fell to $217000.0 in Q2 2026, from $1.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.6 million in Q4 2024 to a low of -$3.9 million in Q4 2025.
• A 5-year average of $155055.6 and a median of $53000.0 in 2023 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 129650.0% in 2024, down 4715.09% in 2024.
• Tracing SMMT's Capital Expenditures over 5 years: stood at -$10000.0 in 2022, then jumped by 120.0% to $2000.0 in 2023, then surged by 129650.0% to $2.6 million in 2024, then tumbled by 249.17% to -$3.9 million in 2025, then soared by 105.61% to $217000.0 in 2026.
• The last three Capital Expenditures figures came in at $217000.0 (Q2 2026), $1.0 million (Q1 2026), and -$3.9 million (Q4 2025), per Business Quant data.